2021
Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis and hepatocellular cancer
Blanc V, Riordan JD, Soleymanjahi S, Nadeau J, Nalbantoglu I, Xie Y, Molitor EA, Madison BB, Brunt EM, Mills JC, Rubin DC, Ng I, Ha Y, Roberts LR, Davidson NO. Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis and hepatocellular cancer. Journal Of Clinical Investigation 2021, 131 PMID: 33445170, PMCID: PMC7773377, DOI: 10.1172/jci138699.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCarcinoma, HepatocellularFatty LiverLiver CirrhosisLiver NeoplasmsMiceMice, KnockoutNeoplasm ProteinsRNA-Binding ProteinsConceptsHuman hepatocellular cancerHigh-fructose dietHepatocellular cancerNonalcoholic fatty liver diseaseFatty liver diseaseExpression of mRNALipogenic gene expressionSpontaneous fibrosisAdvanced fibrosisLiver diseaseLiver functionHepatic steatosisInflammatory pathwaysInflammatory responseFed chowLong-term effectsTissue microarrayHepatic proliferationMRNA expressionFactor overexpressionReduced survivalFibrosisOxidative stressExtracellular matrix organizationSteatosis
2017
Differentiation of Hepatocellular Carcinoma from Other Hepatic Malignancies in Patients at Risk: Diagnostic Performance of the Liver Imaging Reporting and Data System Version 2014.
Fraum TJ, Tsai R, Rohe E, Ludwig DR, Salter A, Nalbantoglu I, Heiken JP, Fowler KJ. Differentiation of Hepatocellular Carcinoma from Other Hepatic Malignancies in Patients at Risk: Diagnostic Performance of the Liver Imaging Reporting and Data System Version 2014. Radiology 2017, 286: 158-172. PMID: 28853673, DOI: 10.1148/radiol.2017170114.Peer-Reviewed Original ResearchConceptsNon-HCC malignanciesArterial phase hyperenhancementRim arterial phase hyperenhancementPositive predictive valueHepatocellular carcinomaPredictive valueData System (LI-RADS) version 2014Diagnostic performancePopulation of patientsHIPAA-compliant institutional review boardLiver Imaging ReportingLR-5 criteriaMalignant liver massesLI-RADS categoryFisher's exact testInstitutional review boardClinical followExtrahepatic malignanciesPathology findingsCommon findingLiver massExact testIndependent sample t-testMalignancyImaging Reporting
2014
Role of liver biopsy in nonalcoholic fatty liver disease.
Nalbantoglu I, Brunt E. Role of liver biopsy in nonalcoholic fatty liver disease. World Journal Of Gastroenterology 2014, 20: 9026-37. PMID: 25083076, PMCID: PMC4112884, DOI: 10.3748/wjg.v20.i27.9026.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonalcoholic fatty liver diseaseFatty liver diseaseLiver diseaseLiver biopsyPediatric nonalcoholic fatty liver diseaseNASH Clinical Research NetworkLocation of fibrosisSpecific histologic lesionsCardiovascular risk factorsExcess alcohol intakeChronic liver diseaseClinical Research NetworkClinical research trialsLiver biopsy evaluationLimitations of biopsyNon-invasive testingImportant liver diseaseHepatic manifestationNecroinflammatory activityMetabolic syndromeAlcohol intakeHistologic findingsHepatic triglyceridesRisk factorsBiopsy evaluation